159 related articles for article (PubMed ID: 35791438)
1. The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models.
Robillard L; Liao M; Nguyen M; Harding TC; Simmons AD; Dusek RL
J Immunother; 2022 Oct; 45(8):335-348. PubMed ID: 35791438
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
[TBL] [Abstract][Full Text] [Related]
3. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
Guffanti F; Chilà R; Bello E; Zucchetti M; Zangarini M; Ceriani L; Ferrari M; Lupi M; Jacquet-Bescond A; Burbridge MF; Pierrat MJ; Damia G
Neoplasia; 2017 Jan; 19(1):35-42. PubMed ID: 27988457
[TBL] [Abstract][Full Text] [Related]
6. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial immunotherapy induces tumor-infiltrating CD8
Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
[TBL] [Abstract][Full Text] [Related]
10. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models.
Zhou Y; Fu C; Kong Y; Pan D; Wang Y; Huang S; Li Z; Ning Z; Lu X; Shan S; Xin L
Anticancer Drugs; 2019 Oct; 30(9):909-916. PubMed ID: 30998512
[TBL] [Abstract][Full Text] [Related]
11. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
12. Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy.
Shibutani T; Goto R; Miyazaki I; Hashimoto A; Suzuki T; Ishida K; Haruma T; Osada T; Harada T; Fujita H; Ohkubo S
Sci Rep; 2023 May; 13(1):8821. PubMed ID: 37258621
[TBL] [Abstract][Full Text] [Related]
13. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
14. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
16. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
18. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
[TBL] [Abstract][Full Text] [Related]
20. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
